Seeking participants for Parkinson’s disease clinical trial

TEMPO-3 Trial

This is a study of an experimental treatment (referred to as “study drug”) called CVL-751 as a possible treatment for Parkinson’s disease. An experimental treatment is one that has not been approved by the United States (US) Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA) in Australia or any other regulatory agency .

The main purpose of this study is to learn how well the study drug works and how safe the study drug is and to find the right dose. If you choose to participate in this study, you may receive the study drug, or you may receive placebo. A placebo is a medication with no active ingredients. It looks like the real thing but is not. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.

Anticipated date that enrolment will close: 31 December 2021

Who can take part

Participants must:

  • be aged 40 to 80 years, inclusive
  • agree to use acceptable (at minimum) or highly effective birth control if they are sexually active participants of childbearing potential
  • be capable of giving signed informed consent
  • be able, in the opinion of the investigator, to understand the nature of the trial and comply with study's requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures
  • have been diagnosed with Parkinson's disease that is consistent with the UK Parkinson’s Disease Society Brain Bank diagnostic criteria, with bradykinesia
  • return a completed self-reported home diary for motor function status (Hauser diary) during the screening period

What is involved for you

You will be in this study for approximately 35 weeks, which includes a screening visit, 27 week treatment period and a safety follow up phone call. You will need to come to the study center at least 11 times over this period. Different tests and procedures will be performed at each visit, depending on the type of visit (for example, a screening visit or a treatment visit).

The study is divided into 3 time periods: a 4 week screening/baseline period, a 27-week treatment period, and a 4-week post-treatment safety follow-up period. If the study doctor determines that you meet all the requirements to be in the study, you will be randomly assigned (like flipping a coin) to receive either the study drug or the placebo.

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2020.077
Parkinson's Research Team
(03) 9342 8182